Myotonic dystrophy type 2 (MD2) is an inherited neuromuscular disorder characterized by progressive myotonia, muscle weakness, and severe muscle wasting. The disorder is caused by expansion of the adenosine-tryposphoric acid (CTG) polymer repeat sequences in the ZNF9 (CCTG) gene and typically manifests in adults. Unlike myotonic dystrophy type 1, which often begins in childhood or adolescence, symptoms of MD2 may occur later in life, which can make diagnosis difficult in the early stages. Patients may also experience various extramuscular manifestations, such as cataracts, insulin resistance, and abnormal heart rhythms, adding to the complexity of the clinical presentation and treatment of this disorder.
History of the disease and interesting historical facts
Myotonic dystrophy was first described in medical practice at the beginning of the 20th century, but the identification of various types of the disease occurred much later. Let us note the key moments in the history of the disease:
- 1900 - The first case of myotonic dystrophy was described by the American neurologist S. P. Krippelin.
- 1966 - Filigree studies and definitions revealed a full nosological designation for myotonic dystrophy type 1, while type 2 remained ignored.
- 1993 – Discovery of CTG mutations in the DMPK gene, which became the basis for the diagnosis of myotonic dystrophy type 1.
- 2001 – Identification of the CCTG mutation in the ZNF9 gene as the cause of myotonic dystrophy type 2.
Each of these steps has significantly advanced our understanding of the mechanisms of the disease and opened the way for further research to develop more effective treatments.
Epidemiology
Myotonic dystrophy type 2 has a low prevalence and is considered a rare disease. Epidemiological studies show that the incidence is approximately 1 in 100,000 people. The incidence varies depending on the geographic region and ethnic group. There has been an increase in the incidence of MiD2 over the past few decades, which may be due to improved diagnostic methods, physician awareness, and thus, greater chances of early detection.
Genetic predisposition to this disease
Myotonic dystrophy type 2 is caused by an increase in the number of repeating sequences CCTG in exon 16 of the ZNF9 gene. The normal sequence may contain from 5 to 30 repeats, while in the case of the disease their number can reach several hundred or even thousands. This is a gene encoding a Zn-containing protein involved in the regulation of transcription and cellular signaling. A change in the number of repeats leads to a disruption of gene function and, as a result, cellular function, causing neuromuscular disorders.
Risk factors for the development of this disease
The main risk factors that contribute to the development of myotonic dystrophy type 2 include:
- Heredity - the disease is transmitted in an autosomal dominant manner.
- Gender - the disease is more common in men, although women may also show signs of the disease.
- Family history - Having a family history of myotonic dystrophy increases the risk of developing it.
- Age - Although the disease can manifest at any age, symptoms are more often seen in adults.
Diagnosis of this disease
Diagnosis of myotonic dystrophy type 2 includes several stages:
- The main symptoms are myotonia, muscle weakness, difficulty chewing and swallowing, and frequent falls.
- Lab tests: Blood test for creatine kinase levels, which may be elevated in cases of muscle injury.
- Radiological tests: Magnetic resonance imaging can detect changes in muscle tissue.
- Other diagnostic tests include genetic testing to detect the CCTG mutation in the ZNF9 gene.
- Differential diagnosis: it is necessary to exclude other muscular dystrophies, myasthenia, various forms of myopathies and other neurological disorders.
Treatment
Treatment of myotonic dystrophy type 2 is complex and depends on the severity of symptoms and the clinical condition of the patient. The main approaches include:
- General treatment: exercise therapy, physiotherapy, supportive therapy to improve quality of life.
- Pharmacological treatment: use of muscle relaxants to reduce myotonic symptoms.
- Surgical treatment: correction of orthopedic deformities, if any.
- Other treatments include using alternative medicine and dietary supplements to improve the condition.
List of medications used to treat this disease
Medications that may be used to manage the symptoms of myotonic dystrophy type 2 include:
- Baclofen
- Carbamazepine
- Tizanidin
- Dantrolene
- Midocazolam
Disease monitoring
Monitoring the condition of patients with myotonic dystrophy type 2 involves regularly assessing the patient's condition and treating its complications. Evaluation may include:
- Control stages: regular consultations with a neurologist, assessment of respiratory functions, cardiovascular system.
- Prognosis: The disease progresses, but with proper therapy, patients can remain able to work for a long time.
- Complications: cardiomyopathy, deterioration of respiratory function, diabetes and other concomitant pathologies.
Age-related features of the disease
Myotonic dystrophy type 2 has its own manifestations depending on age:
- Childhood and adolescence: symptoms are usually not present, muscle weakness usually begins between the ages of 30 and 50.
- Young and middle-aged: patients begin to experience myotonic symptoms, muscle weakness, but can generally lead an active lifestyle.
- Older adults: more severe muscle atrophy, frequent falls, problems with coordination and decreased quality of life.
Questions and Answers
- What are the main symptoms of myotonic dystrophy type 2? The main symptoms include myotonia, muscle weakness, difficulty swallowing and chewing, and frequent falls.
- Can myotonic dystrophy type 2 be cured? Treatment is aimed at managing symptoms and improving quality of life; there is currently no complete cure.
- How is the risk of passing on a disease to offspring determined? Myotonic dystrophy type 2 is transmitted in an autosomal dominant manner, meaning that each offspring has a 50% chance of having the disease.
- What medications are most commonly used to treat myotonic dystrophy type 2? Muscle relaxants such as baclofen and analgesics such as carbamazepine are used.
- What is the prognosis for life and activity of patients with myotonic dystrophy type 2? With proper treatment, patients can lead an active lifestyle, but disease progression requires ongoing monitoring and treatment adjustments.
